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The glyoxalase system is the most important pathway for the detoxification of methylglyoxal (MG), a highly reactive dicarbonyl com-
pound mainly formed as a by-product of glycolysis. MG is a major precursor of advanced glycation end products (AGEs), which are
associated with several neurodegenerative disorders. Although the neurotoxic effects of MG and AGEs are well characterized, little is
known about the glyoxalase system in the brain, in particular with regards to its activity in different neural cell types. Results of the
present study reveal that both enzymes composing the glyoxalase system [glyoxalase-1 (Glo-1) and Glo-2] were highly expressed in
primarymouse astrocytes compared with neurons, which translated into higher enzymatic activity rates in astrocytes (9.9- and 2.5-fold,
respectively). The presence of a highly efficient glyoxalase system in astrocytes was associated with lower accumulation of AGEs com-
pared with neurons (as assessed by Western blotting), a sixfold greater resistance to MG toxicity, and the capacity to protect neurons
against MG in a coculture system. In addition, Glo-1 downregulation using RNA interference strategies resulted in a loss of viability in
neurons, but not in astrocytes. Finally, stimulation of neuronal glycolysis via lentiviral-mediated overexpression of 6-phosphofructose-
2-kinase/fructose-2,6-bisphosphatase-3 resulted in increased MG levels and MG-modified proteins. Since MG is largely produced
through glycolysis, this suggests that the poor capacity of neurons to upregulate their glycolytic flux as comparedwith astrocytesmay be
related to weaker defense mechanisms against MG toxicity. Accordingly, the neuroenergetic specialization taking place between these
two cell types may serve as a protective mechanism against MG-induced neurotoxicity.
Introduction
The glyoxalase system is a ubiquitous enzymatic pathway that
catalyzes the glutathione (GSH)-dependent detoxification of
methylglyoxal (MG) and other reactive dicarbonyl compounds,
thereby playing a major role in the cellular defense against glyca-
tion and oxidative stress (Thornalley, 1993; Kalapos, 2008b). It
comprises two enzymes: Glo-1 and Glo-2. Glo-1 catalyzes the
conversion of the hemithioacetal formed by the nonenzymatic
reaction of GSH with MG, to S-D-lactoylglutathione. S-D-
Lactoylglutathione is then converted to D-lactate by Glo-2, which
recycles GSH in the process (Fig. 1) (Thornalley, 1993).
The accumulation of MG is highly deleterious, as this metab-
olite is one of the most potent glycating agents present in cells. It
readily reacts with lipids and nucleic acids and with lysine and
arginine residues of proteins to form advanced glycation end
products (AGEs) such as the hydroimidazolone MG-H1, argpy-
rimidine, N -(1-carboxyethyl)lysine (CEL), and MG-derived
lysine dimer (Rabbani and Thornalley, 2010). AGEs are impli-
cated in various pathophysiologicalmechanisms, including those
associated with diabetic complications (cataracts, retinopathy,
nephropathy, angiopathy), aging, and neurodegenerative disor-
ders (Wautier and Guillausseau, 2001; Mu¨nch et al., 2010).
MG is inevitably produced (either spontaneously or enzymati-
cally) as a by-product of fatty acid, protein, and glucosemetabolism
(Thornalley, 1996; Kalapos, 1999). The glycolytic pathway is the
most important endogenous source ofMGvia the fragmentation of
the triosephosphates glyceraldehyde-3-phosphate (glyceraldehyde-
3P) and dihydroxyacetone phosphate (DHAP) (Fig. 1). It is esti-
mated that MG production accounts for 0.1–0.4% of the glycolytic
flux (Kalapos, 2008a).
The brain has very high energy requirements: although it rep-
resents only 2% of the body weight, it is responsible for 25% of
the overall glucose consumption (Magistretti, 2008). As the cel-
lular production of MG is linked to the glycolytic pathway, this
suggests that the glyoxalase system is of primary importance to
protect the brain against the accumulation of AGEs. A large body
of evidence demonstrates that cerebral glucose consumption is
not homogenous and that cell-type-specific differences exist in
terms of energymetabolism. For instance, according to the astro-
cyte–neuron lactate shuttle (ANLS), glutamate uptake into astro-
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cytes during synaptic activation causes a stimulation of anaerobic
glycolysis and glucose uptake in astrocytes. Lactate produced in as-
trocytes is shuttled to neurons, where it may be used as an energy
substrate in theKrebscycle following its conversion topyruvate, thus
bypassing glycolysis (Magistretti, 2009). Interestingly, it has been
demonstrated that in contrast to astrocytes, neurons have a poor
capacity to upregulate glycolysis (Almeida et al., 2001; Porras et al.,
2004;Herrero-Mendez et al., 2009). Recent evidence shows that one
mechanism explaining this characteristic might be the constitutive
proteasomal degradation of 6-phosphofructose-2-kinase/fructose-
2,6-bisphosphatase-3 (Pfkfb3), which results in low levels of
fructose-2,6-bisphosphate (fructose-2,6-P2), a potent activator of
phosphofructokinase (Fig. 1) (Herrero-Mendez et al., 2009).
Despite the fact that the brain is highly dependent upon glu-
cose consumption, little is known about its glyoxalase system,
especially with regards to potential differences and complemen-
tarities between neural cell types, which may arise from their
specific energy metabolic profiles. The aim of this study was thus
to characterize the glyoxalase system in astrocytes and neurons in
relation to the formation of AGEs.
Materials andMethods
Cell cultures
Experiments were conducted in accordance with the Swiss Federal Guide-
lines for Animal Experimentation and were approved by the Cantonal Vet-
erinary Office for Animal Experimentation (Vaud, Switzerland).
Astrocytic cultures. Primary cultures of cerebral cortical astrocytes were
prepared fromnewborn (1- to 2-d-old) OF1mice (Charles River Laborato-
ries) as previously described (Gavillet et al., 2008). Cells were plated in 35
mm dishes and maintained in DMEM (D7777, Sigma-Aldrich) containing
25mMglucose and supplementedwith 44mMNaHCO3, 10ml/L antibiotic/
antimycotic solution (Invitrogen), and 10% FCS (Bioconcept), and incu-
bated at 37°C in an atmosphere containing 5% CO2 and 95% air.
Experiments were performed on confluent 21-d-old cultures.
Neuronal cultures. Primary cultures of cortical neurons were prepared
from E17 OF1 mice embryos (Charles River Laboratories) as previously
described (Allaman et al., 2010). Neurons were plated in 35 mm dishes
andmaintained in Neurobasal medium (which contains 25 mM glucose)
supplemented with B27, GlutaMAX, penicillin (50 U/ml), and strepto-
mycin (50g/ml) (Invitrogen) at 37°C in a humidified atmosphere con-
taining 5% CO2 and 95% air and were used at DIV 14. These culture
conditions typically produced 93%pure neuronal cultures, as assessed by
MAP2 and GFAP coimmunostaining.
CHO. CHO cells were obtained from LGC Standards (Molsheim).
Stock cultures were kept in 150 ml flasks in DMEM supplemented with
10% FCS, penicillin (50 U/ml), and streptomycin (50 g/ml), and were
passaged once a week. To perform experiments, cells were plated in 35
mm dishes until they reached confluence, at which point they were
treated as described in the following section. Cells under passage 15 were
used.
Cell treatment with MG
If not otherwise specified, culture mediumwas renewed 2 h before treat-
ment with MG. To avoid interference with subsequent biochemical
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Figure 1. Schematic representation of themainmetabolic pathways involved inMG production and elimination. A,B, MG is formedmainly by the fragmentation of the glycolytic intermediates
glyceraldehyde-3P and DHAP (A), but also from themetabolism of lipids and proteins (B). PFK is the rate-limiting step of glycolysis and thus constitutes an important regulatory site, and one of its
most potent allosteric activators is fructose-2,6-P2. Fructose-2,6-P2 levels are controlled by the Pfkfb, which ismost abundantly expressed in astrocytes comparedwith neurons (Herrero-Mendez et
al., 2009). C, MG is detoxified principally via the glyoxalase system, which consists of the enzymes Glo-1 and Glo-2. The first step of MG detoxification requires its spontaneous reaction with GSH to
formahemithioacetal, which is used as a substrate by Glo-1 to form S-lactoylglutathione. Glo-2 then catalyzes the transformation of S-lactoylglutathione into D-lactate, recycling GSH in the process.
D, The pentose phosphate pathway is linked to MG detoxification via the formation of NADPH, which is required for the recycling of GSH from its oxidized form (GSSG) via the action of glutathione
reductase (GR).
Be´langer et al. • The Glyoxalase System in Astrocytes and Neurons J. Neurosci., December 14, 2011 • 31(50):18338–18352 • 18339
assays, serum- and phenol red-free culture medium was used. For
astrocytes, this medium consisted of DMEM (D2902; Sigma-Aldrich)
supplemented with 44 mM NaHCO3 and 10 ml/L antibiotic/antimycotic
solution (Invitrogen) and complemented to 25mM glucose to give rise to
amedium that is strictly equivalent to the normal culturemedium except
for phenol red and serum. This medium was also used for the treatment
of CHO cells with MG.
For neurons, Neurobasal medium without phenol red was obtained
from Invitrogen (catalog no. 12348-017) and complemented to give rise
to a medium otherwise identical to that in which cells were grown, with
the other exception that B27 supplement without antioxidants was used.
Regular B27 supplement contains GSH and other antioxidants, which
may interfere or mask some effects of MG, in particular those related to
the changes of cellular redox status. GSH is also used by the glyoxalase
system to detoxify MG, and thus had to be removed to get an accurate
evaluation of the intrinsic response of neurons to MG. Treatment with
MG was induced by the addition of a 100 stock solution in the culture
medium.
Coculture experiments
Bilaminar cocultures were used to evaluate the effects of MG treatment
on neuronal survival in the presence or absence of astrocytes. Astrocytes
were rinsed and medium was replaced with 2 ml of fresh Supplemented
Neurobasal medium (see above, Cell treatment with MG). Cells were
incubated at 37°C in an atmosphere containing 5% CO2 and 95% air for
2 h, after which cocultures were initiated by transferring neurons grown
on coverslips on top of the astrocyte layer (neurons facing up). Neurons
cocultured with astrocytes were compared with primary neuronal cul-
tures prepared in parallel and treated exactly the sameway, i.e., they were
transferred in new dishes containing identical Neurobasal medium pre-
incubated for 2 h but in the absence of astrocytes. Two hours after trans-
ferring the coverslip, primary neurons and cocultures were exposed to
MG as described above. Neuronal viability was assessed 24 h following
treatment with MG using the MTT reduction assay.
Glyoxalase activity
Cell culture medium was replaced (see above, Cell treatment with MG)
24 h before the assay. Cells were rinsed with ice-cold PBS and lysed with
300 l of buffer containing 10 mM HEPES, pH 7.0, 0.02% Triton X-100,
and 100g/ml BSA. Samples were harvested and sonicated briefly on ice
and centrifuged at 16,000 g for 30 min at 4°C. Glo-1 and -2 activities
weremeasured using amodification fromapreviously publishedmethod
(Thornalley and Tisdale, 1988). Tomeasure Glo-1 activity, 50l of sam-
ple was loaded onto a UV microplate (Microtiter; ThermoFisher Scien-
tific) and 200l of reactionmix was added. Reactionmix consisted of 60
mM sodium phosphate buffer, pH 6.6, containing 4 mM GSH and 4 mM
MG, and was preincubated for 10 min at 37°C. S-Lactoylglutathione
synthesis was followed bymeasuring the absorbance at 240 nm every 15 s
for 5 min at 25°C (Safire 2; Tecan). To measure Glo-2 activity, 100 l of
sample was loaded onto a UV microplate and 150 l of reaction mix was
added. Reaction mix consisted of 65 mM Tris-HCl, pH 7.4, containing 350
MS-lactoylglutathione (WakoPureChemicals).S-Lactoylglutathione con-
sumptionwas followedbymeasuring theabsorbanceat240nmevery30s for
10 min at 25°C (Safire 2; Tecan). The protein content was measured using
the remaining cell lysate using the BCA protein assay reagent kit (Thermo
Scientific) according to the manufacturer’s instructions. Glo-1 and -2
activities were expressed as milliunits per milligram of protein, where
1 unit is the amount of enzyme required to catalyze the formation
(Glo-1) or utilization (Glo-2) of 1 mol of S-lactoylglutathione per
minute under assay conditions.
Western blot analysis
Cells were harvested in 80 l of lysis buffer (62 mM Tris-HCl, pH 6.8, 50
mM DTT, 0.3% SDS) containing protease (Complete; Roche) and phos-
phatase (Sigma-Aldrich) inhibitor cocktails. Loading buffer (giving rise
to final concentrations of 62 mM Tris-HCl, pH 6.8, 10% glycerol, 1%
SDS, 0.1mMDTT, and 0.005% bromophenol blue) was added to protein
samples (10–20g) before denaturing at 100°C for 5 min. Proteins were
resolved on NuPAGE 10% Bis-Tris minigels using MES SDS running
buffer (Invitrogen) and transferred to Immobilon-P PVDF membranes
(Millipore). The membranes were blocked for 1 h in PBS containing
0.1%Tween 20 (PBST) and 5%drymilk and then incubated overnight at
4°C with antibodies directed against Glo-1 (rabbit polyclonal, 1:75,000
dilution; Santa Cruz Biotechnology), Glo-2 (goat polyclonal, 1:10,000
dilution; Santa Cruz Biotechnology), AGEs [mouse monoclonal; clone
6D12, 1:2000 (see Fig. 7C) or 1:5000 (see Fig. 8B) dilution; TransGenic]
or argpyrimidine (mouse monoclonal, 1:500 dilution; JaICA). After
washing with PBST, the blots were probed with the appropriate HRP-
conjugated secondary antibody (GE Healthcare) diluted 1:15,000 in
PBST plus 5% dry milk. After extensive washing with PBST, the peroxi-
dase activitywas detected by chemiluminescence using the ECLdetection
system (GEHealthcare) andKodakBioMaxMR film.-Actin expression
was assessed to ensure equal loading. The PVDF membranes were
stripped for 30min at 50°C in buffer containing 62mMTris-HCl, pH 6.8,
100mM -mercaptoethanol, and 2% SDS.Membranes were washed sev-
eral times with PBST and probed as described above using a mouse
monoclonal antibody against-actin diluted 1:500,000 (Sigma-Aldrich).
Film was digitized using a CoolSNAP cf CCD camera (Photometrics).
Quantitative PCR
Total RNA was isolated from cultured cells using a NucleoSpin RNA II
kit (Macherey-Nagel) according to the manufacturer’s instructions.
RNA concentration was determined using a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies). The first strand of cDNAwas
synthesized from 100 ng of total RNA (60min at 37°C, followed by 5min
at 95°C) using the High Capacity RNA-to-cDNA Reverse Transcription
system (Applied Biosystems). One twenty-fifth of the resulting cDNA
was amplified by quantitative PCR (qPCR) with the ABI PRISM 7900
system (Applied Biosystems). PCR mix was composed of 6 ng of cDNA
and 200 nM forward and reverse primers in 10l of 1 SYBRGreen PCR
MasterMix (Applied Biosystems). Primer sequenceswere designed using
primer Express 3.0 software (Applied Biosystems) and oligonucleotides
were synthesized by Microsynth. Forward and reverse primer sequences
were as follows: 5-CCT GAT GAC GGG AAA ATG AAA G-3 and 5-
GCC GTC AGG GTC TTG AAT GA-3 (Glo-1; GenBank NM_025374)
and 5-AGG CGC TGC TTG AAG TCT TG-3 and 5-AAG GTT GTT
TAC GGT GTA TTC ATG AC-3 (Glo-2; GenBank accession number
NM_024284.2). The specificity of PCR amplification for each set of
primers was checked by the presence of a single sharp peak in themelting
curve analysis. Datawere computed using the sequence detector software
SDS 2.3 (Applied Biosystems) and analyzed using a macro developed by
the genomic platform of Geneva University (Frontiers in Genetics,
UNIGE). Delta-CT relative quantification (Ct) was used and data
were expressed as percentage of astrocytic expression.
Immunofluorescence and image acquisition
Female OF1 mice were perfused-fixed with 4% paraformaldehyde and
brainswere cryoprotected in a 30% sucrose solution and frozen at80°C
until use. Free-floating coronal sections (30 m) were obtained by cry-
ostat sectioning and kept in PBS containing 0.05% sodium azide at 4°C
until use. For double immunofluorescence staining, sections were rinsed
in PBS and permeabilized for 30 min at room temperature with PBS
containing 0.25% Triton X-100. Sections were then incubated in PBS
containing 5% BSA and 0.05% Triton X-100 (PBS-BT) for 1 h at room
temperature to block nonspecific binding before incubationwith a rabbit
polyclonal antibody against Glo-1 (1/250 dilution; catalog no. sc-67351;
Santa-Cruz Biotechnology) in PBS-BT overnight at 4°C. Sections were
rinsed thoroughly and incubated for 1 h at room temperature in PBS-BT
containing 1/250 donkey anti-rabbit secondary antibody labeledwith the
green fluorescent Alexa Fluor 488 dye (Invitrogen). After extensivewash-
ing, sections were sequentially stained (using the procedure described
above for Glo-1) with mouse monoclonal antibodies directed against
either GFAP (1/600 dilution; catalog no. G3893; Sigma-Aldrich) or
NeuN (1/600 dilution; catalog no. MAB377; Millipore) followed by in-
cubation with donkey anti-mouse secondary antibody labeled with the
red fluorescent Alexa Fluor 568 dye (Invitrogen). Sections were finally
incubated with 0.2 g/ml Hoechst to stain nuclei, rinsed in phosphate
buffer (120 mM, pH 7.4), and mounted with an anti-bleaching medium
(DABCO; Sigma-Aldrich). Single staining with each primary antibody
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(Glo-1, GFAP, or NeuN) and its respective secondary antibody was also
performed as a control experiment according to the same protocol. For
each individual target, the staining patterns observed in single and dou-
ble immunofluorescence experiments were similar.
Image acquisitions were performed as the maximum projection of a
stack of 12 imageswith 1mstep size (except for Fig. 3C, which consisted
of 30 images with 300 nm step size) on a confocal microscope (LSM 710;
Zeiss) with a Plan Apochromat 40 1.3 oil-immersion objective. Image
processing was performed using the Imaris software v6.4.2, in surpass
mode. To avoid any cross talk, the images were acquired in sequential
mode using laser lines at 405 nm (30mW), 488 nm (25mW), and 561 nm
(15 mW) with 1–4.5% transmission; 8 average line method with a pixel
dwell of 0.79 s; and bandpass of 410–480 nm for DAPI, 490–550 nm
for Alexa 488, and 565–700 nm for Alexa 568. To obtain an appropriate
resolution, a format of 1024 1024 with a zoom at 1.2 was used, corre-
sponding to 148 nm/pixel (except for Fig. 3C; format  354  222,
zoom 1.4, and pixel size 148 nm). The pinhole aperture was 1 airy
unit.
Cell dissociation and FACS analysis
Young C57BL/6-Tg (hGFAP-eGFP) mice (23–27 d old) were deeply
anesthetizedwith isoflurane (Attane;Minrad) and killed by decapitation.
The brain was rapidly removed and cerebral cortices were dissected out
and placed in ice-cold calcium and magnesium-free modified HBSS
(mHBSS) containing 25 mM D-glucose and 10 mM HEPES (Invitrogen).
Cortices were cut into 1 mm3 pieces and enzymatically digested with
20 U/ml papain (Worthington) in mHBSS containing 0.12 mg/ml
L-cysteine (Sigma-Aldrich) and 1 U/ml DNaseI (Worthington) for 45
min at 35°C under gentle agitation. Papain activity was quenched for 5
min using a 1% solution of BSAdiluted in FCS and tissuewas centrifuged
2 min at 200  g to remove the enzyme solution. The tissue was then
dissociated by gentle trituration in ice-cold mHBSS and the cell suspen-
sion was collected in a tube containing DNaseI. This step was repeated
three times. Cells were then centrifuged for 8 min at 500  g, the pellet
was resuspended in 2 ml of mHBSS, and cell clusters and debris were
removed by filtration through a 40 m cell strainer (Falcon; BD Biosci-
ences). Finally, 2l of propidium iodide (Fluka), a fluorescent cell death
indicator, was added to the cell suspension.
Cell suspensionswere individually sorted by FACSusing a flow cytom-
eter with Diva option (FACS Vantage SE; Becton Dickinson) equipped
with a Coherent Enterprise laser simultaneously emitting 360 and 488
nm in position 1 (5 fluorescence), and a Coherent Helium-Neon emit-
ting 630 nm in the third position (2 fluorescence). Data were collected
and analyzed using FACSDiva software (Becton Dickinson). One hun-
dred thousand to 130,000 viableGFP cells were typically obtained using
this procedure. Sorted cells were harvested in PBS, pelleted, and resus-
pended in lysis buffer, following which Glo-1 enzyme activity was as-
sessed as described above. The enrichment of the cell fractions was
assessed using qPCR analysis. Astrocytic markers were 10- to 50-fold
higher in GFP cell fraction, while the oligodendrocytes and the neuro-
nal and the microglial markers were 5- to 20-fold enriched in the GFP
cell fraction.
MTT viability assay
ForMTT determination in coculture and primary culture experiments, a
20 stock solution of MTT was added directly to the culture medium to
give rise to a final concentration of 0.2 mg/ml (cocultures and neurons)
or 0.1 mg/ml (astrocytes), and cells were incubated for 20 min at 37°C in
an atmosphere containing 5% CO2 and 95% air. The medium was then
removed by aspiration, and the reaction was stopped by the addition of 1
ml of DMSO. For coculture experiments, the glass coverslips bearing
neurons were placed in a new dish before the addition of DMSO. The
amount of reduced MTT (formazan) solubilized in DMSO was then
determined spectrophotometrically using absorbance at 560 nm (Safire
2; Tecan). Results are expressed as percentage of control values.
GSH assay
Total intracellular GSH levels ([GSx]i, where GSx reduced form GSH
oxidized form GSSG) were determined spectrophotometrically as previ-
ously described (Allaman et al., 2010). Absolute values were calculated
from a standard curve of known amounts of GSSG, and intracellular
GSH levels were expressed as nanomoles of GSx equivalent permilligram
of protein.
NADP/NADPH assay
Cycling assays for nicotinamide adenine dinucleotides were adapted
from previously published methods (Matsumura and Miyachi, 1980;
Zerez et al., 1987). Cells were rinsed three times with ice-cold PBS, har-
vested in 300 l of ice-cold carbonate-bicarbonate buffer (100 mM
Na2CO3, 20 mM NaHCO3 containing 10 mM nicotinamide to inhibit
NADase), and quickly frozen on dry ice. Samples were thawed in a room
temperature water bath and immediately chilled on ice. Extracts were
centrifuged at 12,000  g for 30 min at 4°C and half of the supernatant
was heated at 60°C for 30 min to denature NADP. Fifty microliters of
both the heated extract (containing NADPH only) and the unheated
extract (containing NADP and NADPH) were loaded onto a 96-well
microplate along with blanks (carbonate-bicarbonate buffer) and stan-
dards of knownNADPH (Roche) concentrations dissolved in carbonate-
bicarbonate buffer. Then 150 l of a reaction mixture was added into
eachwell and the absorbancewas followed spectrophotometrically at 570
nm every 15 s over a 5min period (Safire 2; Tecan). Reactionmixturewas
prepared right before use and contained 130 mM bicine, 5.3 mM EDTA,
0.6 mM MTT, 2.2 mM phenazine ethosulfate, 3.3 mM glucose-6-
phosphate, and 2.5 U/ml glucose-6-phosphate dehydrogenase (G6378;
Sigma-Aldrich). Blanks values were subtracted from all samples and
NADP amounts were calculated by subtracting NADPH values from
total NADPNADPH values. The protein content was measured using
the remaining cell lysate using the BCA protein assay reagent kit accord-
ing to the manufacturer’s instructions and used for normalization. Val-
ues are expressed as nanomoles per milligram protein.
HPLC
HPLC determinations were conducted using a method previously de-
scribed for the measurement of free and reversibly bound MG (Chaplen
et al., 1998). Briefly, cells were rinsed twice with PBS and harvested in
0.45N perchloric acid (PCA) containing 10 M 5-methylquinoxaline (5-
MQ) (Sigma-Aldrich) as an internal standard. For each sample, two 35
mm dishes were pooled in a total volume of 150 l and derivatized with
1 mM o-phenylenediamine (Sigma-Aldrich) for 15 h at room tempera-
ture and centrifuged at 12,000  g for 30 min to remove PCA-
precipitated materials. The resulting 2-methylquinoxaline (2-MQ) was
measured byHPLC using aWaters Alliance 2795HPLC system (Waters)
with a Waters 996 photodiode array detector (scanning wavelength, 315
nm) as previously described (Chaplen et al., 1996) with modifications. A
150l samplewas injected onto the reverse-phase column (BDSHypersil
C18 100 4.6mm; 3mparticle size) fitted with a BDSC18 5MGuard
precolumn (ThermoFisher Scientific). Isocratic elution was performed
with buffer A consisting of 80% 10mMKH2PO4, pH 2.5, and 20%HPLC
grade acetonitrile (Fisher Scientific) at a constant flow rate of 1ml/min. A
2 min wash step with buffer B (20% 10 mM KH2PO4, pH 2.5, and 80%
acetonitrile) was included between each sample. Peak area was deter-
mined using an automated integrator (MassLynx v 4.0, Waters), and
2-MQ concentrations were calculated in relation to the internal standard
(5-MQ) using a standard curve of MG (ranging from 0 to 500 pmol)
derivatized and processed in parallel with the samples. Average retention
times for 2-MQ and 5-MQ were 5.1 and 9.9 min, respectively. Average
protein concentrations for each treatment group were determined in a
separate set of dishes using the BCA assay and used for normalization.
siRNA transfection
Specific Glo-1 downregulation in astrocytes was achieved using Stealth
Select RNAi siRNAs (ref. no. Glo1/MSS27278; Invitrogen). For each 35
mm dish, 100 pmol of siRNA and 5.5 l of HiPerFect Transfection Re-
agent (Qiagen) were diluted in 90 l of DMEM (without serum and
antibiotics) and vortexed at low speed for 2 s. After a 10 min incubation
period at room temperature, the transfection complex was added drop-
wise to 80% confluent astrocytic cultures. Control groups (mock siRNA)
were transfected with Stealth siRNA negative controls (Lo GC complex
#2; Invitrogen). siRNA efficacy was assessed using the glyoxalase enzyme
activity assay and by Western blotting. Glo-1 siRNA treatment typically
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resulted in a 75% decrease in Glo-1 enzyme activity specifically, begin-
ning 24 h following treatment and lasting for at least the following 96 h
(data not shown). Experiments were conducted within this time frame.
Lentiviral vector production
The cDNA coding for Glo-1 (GenBank accession number NM_025374)
or for Pfkfb3 (GenBank accession number NM_133232.2) was cloned
downstream of the phosphoglycerate kinase (PGK) promoter in a self-
inactivating lentiviral transfer vector (SIN-W-PGK) (De´glon et al.,
2000). A Kozak consensus sequence was inserted upstream of the ATG
codon. To produce a negative control virus (mock virus), a short (42 bp)
noncoding sequence was also cloned into the SIN-W-PGK vector and
processed in parallel with the target genes. For gene silencing in neuronal
cultures, small hairpin RNA (shRNA) constructs specifically targeted
againstmouseGlo-1 and cloned into the pLKO1 lentiviral vector (ref. no.
TRCN0000114844) were purchased from Open Biosystems. The empty
pLKO1 vector was also obtained and used as a negative control for ex-
periments using shRNA (mock shRNA).
Lentiviral vectors were generated using a four-plasmid system [i.e.,
SIN-W-PGK (or pLKO1 for shRNA delivery), pCMVR8.92, pRSV-
Rev, and pMD2.G] by transient calcium phosphate transfection of 293T
cells as previously described (Towne and Aebischer, 2009; Barde et al.,
2010). pCMVR8.92, pRSV-Rev, andpMD2.Gplasmidswere purchased
from Fasteris. Supernatants were collected 72 h later and filtered, and
viral particles were concentrated by ultracentrifugation. Pellets were re-
suspended in PBS containing 0.5% BSA and the p24 antigen content was
determined by ELISA (Gentaur) according to the manufacturer’s in-
structions. Viral stocks were stored at 80°C until use. Neurons were
infected on DIV 3 and experiments were conducted 1 week later. The
amount of virus added was 25 ng for Glo-1 gene silencing and overex-
pression and 200 ng per 35 mm dish for Pfkfb3 overexpression experi-
ments. All experiments using lentiviral vectors were performed in a
biosafety level 2 laboratory.
[3H]-2-Deoxyglucose uptake
Cells were treated with viruses as specified and [3H]-2-deoxyglucose
([ 3H]-2-DG) uptake experiments were conducted as previously de-
scribed (Allaman et al., 2004). Incubation medium consisted of glucose-
free Neurobasal medium supplemented with 5 mM glucose, GlutaMAX,
B27 minus antioxidants, and 1 Ci/ml [ 3H]-2-DG (specific activity,
30–60 Ci/mmol; ANAWA). Results, which represent transporter-
mediated glucose uptake and subsequent phosphorylation, were calcu-
lated by subtracting from total counts the portion that was not inhibited
by the glucose transporter inhibitor cytochalasin B (50M) added 15min
before and during [ 3H]-2-DG incubation. [ 3H]-2-DG uptake is ex-
pressed as percentage of control values.
Lactate release
L-Lactate release into the medium was determined as previously de-
scribed (Allaman et al., 2010). Measurements were made on aliquots of
the culturemediumused for [ 3H]-2-DG, whichwere collected at the end
of the incubation period. Briefly, aliquots (200l) were mixed with 1 ml
of glycine buffer (0.2 M glycine, 0.2 M semicarbazide, pH 10) containing 2
mg/ml NAD and 7U/ml L-lactate dehydrogenase (Roche) and incubated
at 40°C for 1 h. After 20min at room temperature, the amount of NADH
producedwasmeasured in 200l aliquots loaded on a 96-well black plate
with a spectrophotometer (increase in fluorescence; 340 nm excitation/
450 nm emission) (Safire 2; Tecan) and absolute values were determined
from a standard curve of L-lactate.
D-Lactate released into the extracellular space following treatment
with MG was measured using the abovementioned protocol with some
modifications. Seventy microliter aliquots of culture medium were di-
rectly loaded on a 96-well black plate and 180 l of glycine buffer (0.2 M
glycine, 0.2 M semicarbazide, pH 10) containing 2 mg/ml NAD and 40
U/ml D-lactate dehydrogenase (CPC Biotech) was added. Samples were
incubated for 2 h at room temperature, after whichNADHwasmeasured
as described above. Absolute values were determined from a standard
curve of known D-lactate concentrations. L-Lactate and MG up to 5 mM
were undetectable using this assay. In some cases, samples were diluted
with fresh culturemedium in order to obtain valueswithin the linear part
of the standard curve.
Statistical analysis
Data were analyzed for statistical significance by Student’s t test, or by
one-way or two-way ANOVA. Statistically significant one-way ANOVAs
were followed by a post hocDunnett’s multiple-comparison test when all
groups were compared with the control group, or by a Bonferroni’s
multiple-comparison test when comparing all pairs of groups (Prism 4.0;
GraphPad). Two-way ANOVAs were followed by a post hoc Bonferroni’s
multiple-comparison test, except when requiring comparison between
all pairs of groups, inwhich case post hoc analysis wasmade using Tukey’s
multiple-comparison test (R 2.12.0). Significance was accepted at p 
0.05 for all statistical tests.
Results
The glyoxalase system in astrocytes and neurons
To evaluate the intrinsic capacity of astrocytes and neurons to
detoxify MG, Glo-1 and -2 activity rates were determined in pri-
mary cortical cultures. Both enzymes displayed significantly
higher activity in astrocytes compared with neurons. Glo-1 and
-2 activity were, respectively, 9.8 times higher (943.4  69.5 vs
95.4 9.0 mU/mg protein) and 2.5 higher (18.7 0.5 vs 7.4
0.2mU/mgprotein) in astrocytes as comparedwith neurons (Fig.
2A,B). It is also worth noting that Glo-1 activity rates weremark-
edly higher compared with Glo-2 in both cell types (Fig. 2A vs
2B), supporting the notion that the rapid conversion of GSH and
MG to S-lactoylglutathione plays a critical role in the cellular
defense against MG toxicity (Thornalley, 2008).
In accordance with the enzymatic activity measurements,
Western blot analysis revealed that Glo-1 and -2 protein expres-
sion is higher in astrocytes compared with neurons, and this dif-
ference ismore pronounced for Glo-1 than for Glo-2 (Fig. 2C,D).
At the mRNA level, while Glo-1 expression is 3.3 times higher in
astrocytes than in neurons (Fig. 2E), Glo-2 expression is not
significantly different between both cell types (Fig. 2F), suggest-
ing that posttranscriptional mechanisms differentially regulate
Glo-2 expression in astrocytes and neurons.
The end product of MG detoxification via the glyoxalase sys-
tem is D-lactate. In contrast to the L-lactate enantiomer, D-lactate
is poorly metabolized in mammalian neural cells (Brandt et al.,
1984). We thus measured D-lactate release into the extracellular
space as an index to monitor the detoxification of MG by the
glyoxalase pathway in astrocytes and neurons. Importantly, nei-
ther L-lactate nor MG interfered with the D-lactate assay at con-
centrations up to 5 mM (data not shown). For the time course
analysis, astrocytes and neurons were exposed to 500MMGand
aliquots of the culture mediumwere taken over the next 5 h (Fig.
2G). The production of D-lactate occurred significantly more
rapidly in astrocytes than in neurons, in agreement with the
higher Glo-1 and -2 enzyme activity rates reported above. Fur-
thermore, astrocytes completely metabolized the MG bolus
within 5 h, as the addition of 500MMG resulted in the produc-
tion of 513.3  25.4 M D-lactate, which is consistent with the
predicted stoichiometry of the glyoxalase system reaction. In
contrast, neurons were unable to metabolize the entire bolus of
MG added within the same period ([D-lactate]  310.0  18.7
M after 5 h; Fig. 2G). A similar pattern (i.e., faster and more
complete conversion of MG to D-lactate in astrocytes vs neurons
within 5 h) was obtained following exposure to a lower dose (250
M) of MG (data not shown).
We next exposed astrocytes and neurons to increasing con-
centrations of MG and measured the amount of D-lactate
produced after 24 h. As shown in Figure 2H, astrocytes at con-
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centrations higher than 250 M had a capacity to metabolize
significantly higher amounts of MG as compared with neurons.
Exposure of astrocytes to MG up to 2 mM resulted in the nearly
equimolar production of D-lactate, while at higher concentra-
tions MG was not entirely converted into D-lactate. In neurons,
MGwas entirely metabolized to D-lactate only up to a concentra-
tion of 250M (209.2 10.7MD-lactate produced), after which
MGdetoxification was incomplete—D-lactate production reach-
ing a plateau at 535.4 4.6M despite the presence ofMG in the
millimolar range (Fig. 2H). The incomplete detoxification ofMG
at high concentrations is likely accompanied by a toxic effect of
MG, since it significantly decreases astrocytic and neuronal via-
bility at high concentrations (see below).
Results showing an equimolar production of D-lactate from
subtoxic concentrations of MG suggest that the vast majority of
MG is detoxified via the glyoxalase pathway in astrocytes and
neurons, which is consistent with reports demonstrating that the
glyoxalase system is by far the primaryMGdetoxification route in
most cell types (Thornalley, 1996). In addition to the glyoxalase
system, other enzymes such as aldose reductase, aldehyde de-
hydrogenase, and carbonyl reductase can also metabolize MG
(Thornalley, 1993; Kalapos, 1999). The potential compensatory
upregulation of these alternative detoxification enzymes follow-
ing exposure toMG (2mM for 24 h) was assessed in astrocytes by
qPCR; however, no such effect could be observed (data not
shown).
Glo-1 enrichment in astrocytes in vivo
The enrichment of Glo-1 in astrocytes compared with neurons
was confirmed by immunofluorescence in the cerebral cortex
of mice. Glo-1 immunofluorescence showed diffuse staining
throughout the parenchyma with some cells showing more in-
tense immunoreactivity (Fig. 3A,B). Consistent with previous
reports (Chen et al., 2004; Kuhla et al., 2006), Glo-1 immunore-
activity could be observed in both astrocytes (GFAP-positive
cells, arrows) and neurons (NeuN-positive cells, arrowheads);
however, the strongest levels of Glo-1 immunostaining colocal-
ized with the astrocytic marker GFAP (Fig. 3A). In astrocytes,
Glo-1 immunostaining was present in the cell body and in the
main astrocytic processes along the GFAP-positive filaments
(Fig. 3C).
To ensure that the higher Glo-1 immunostaining observed in
astrocytes in the mouse brain has functional implications, we
assessed Glo-1 enzyme activity in astrocytes acutely isolated from
the brain of transgenicmice expressing eGFPunder the control of
the GFAP promoter. To do so, cerebral cortices were gently dis-
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sociated and FACS was used to isolate astrocytes (GFP cells)
from other neural cell types (GFP cells). Our results show that
in acutely isolated brain cells, Glo-1 activity is 2.0  0.3-fold
higher in the astrocyte-enriched cell fraction compared with
other brain cells (n 6 from three independent experiments; p
0.001). It is worth noting that these results are consistent with
those of Cahoy et al. (2008), who have shown, using a similar
technique, a 2.5-fold enrichment of Glo-1 mRNA expression in
acutely isolated mouse astrocytes.
Together, these results indicate that our in vitro observation
that the glyoxalase system is highly efficient in cortical astrocytes
compared with neurons reflects the in vivo situation and support
the notion that this cell-specific distribution has physiological
significance in the intact brain.
MG toxicity in astrocytes and neurons
To determine whether the striking differences observed in the
glyoxalase system capacity of astrocytes and neurons could result
in different resistance to MG toxicity, cultured astrocytes and
neurons were exposed to increasing concentrations of MG and
cell viability was assessed 24 h later using the MTT assay. Dose–
response analysis shows that astrocyteswere six timesmore resistant
to MG toxicity as compared with neurons (LD50  3.39  0.16
mM in astrocytes vs 0.55  0.05 mM in neurons, p  0.001; Fig.
4A). MG toxicity was also assessed using an alternative cell via-
bility assay (calcein-AM uptake). LD50 values were not signifi-
cantly different from those obtained with theMTT assay for both
cell types (data not shown).
MG-induced cell death could be prevented in astrocytes and
neurons by the addition of an equimolar amount of the carbonyl
scavenger aminoguanidine (AG) 30 min before MG (Fig. 4B).
Furthermore, AG reduced by 88 and 86% the amount of D-lactate
produced fromMG in astrocytes and neurons, respectively (data
not shown), which is consistent with the direct scavenging ofMG
byAG, thereby neutralizingMGandmaking it unavailable for the
glyoxalase system.
Previous characterization of the glyoxalase system in CHO
cells—which is a rapidly dividing and thus high energy-
consuming cell line—has shown that they display very highmet-
abolic fluxes to MG and D-lactate compared with other cell types
(Kingkeohoi andChaplen, 2005; Paoli et al., 2010).We thusmea-
sured Glo-1 and -2 activities as well asMG toxicity in this cell line
to obtain a comparison point for the data obtained in astrocytes
and neurons. Glo-1 and -2 activity rates in CHO cells were com-
prised between those observed in neurons and astrocytes (Glo-1,
189.6 4.2 mU/mg protein; Glo-2, 10.7 1.6 mU/mg protein).
When comparing CHO cells to astrocytes, our results show that
Glo-1 and -2 activity rates were, respectively, 5.0-fold and 1.7-
fold higher in astrocytes, suggesting that astrocytes possess a
particularly efficient glyoxalase system. Consistent with the
enzymatic activity data, CHO cells were more resistant than neu-
A Glo-1 GFAP Nuclei Merge
Glo-1 NeuN MergeB
C Glo-1 GFAP Merge
Nuclei
Nuclei
Figure 3. High expression of Glo-1 in astrocytes of themouse cerebral cortex. Coronal sections of mouse brain were immunostainedwith Glo-1 andwith the astrocytic marker GFAP (A, C) or the
neuronal marker NeuN (B). Glo-1 immunostaining was strongest in astrocytes (A, arrows), but was also present in neurons at lower levels (B, arrowheads). C, Scaled-up image of a single astrocyte
in themouse cerebral cortex shows that Glo-1 immunoreactivity is located in the cell body and processes along the GFAP filaments. Representative images from one of three animals are shown.
Nuclei are stained using Hoechst. Scale bars: 15m (A, B) and 7m (C).
18344 • J. Neurosci., December 14, 2011 • 31(50):18338–18352 Be´langer et al. • The Glyoxalase System in Astrocytes and Neurons
rons, but less than astrocyte, to MG toxicity as assessed by the
MTT reduction assay (LD50, 0.91 0.17 mM).
Considering that astrocytes possess amore efficient glyoxalase
system for the detoxification of MG and are significantly more
resistant to MG toxicity than neurons, we next sought to deter-
mine whether astrocytes could provide significant neuroprotec-
tion against MG toxicity. Coculture experiments demonstrate
that the rapid detoxification of MG by astrocytes can indeed be
protective for surrounding neurons, since neurons cultured in
the presence of astrocytes were significantlymore resistant toMG
toxicity than primary neurons (Fig. 4C). Indeed, a concentration
of 2 mM MG was necessary to reduce neuronal viability by half
in our coculture system, which is close to four times the con-
centration required to achieve a similar effect in primary neu-
rons (Fig. 4A,C).
Differential effects of MG on the redox status of astrocytes
and neurons
The first step for the detoxification of MG via the glyoxalase
system is its reaction with GSH to form a hemithioacetal,
which is subsequently used as a substrate by Glo-1 to form
S-lactoylglutathione. Although GSH is recycled in the following
step by the action of Glo-2, exposure to MG is likely to cause a
transient GSH depletion, especially since Glo-2 displays much
slower activity rates than Glo-1 in both astrocytes and neurons
(Fig. 2). According to the extent and duration of this depletion, it
may have important consequences for the cell’s oxidative stress
status, since GSH represents one of the most important antioxi-
dants in mammalian cells (Dringen, 2000). Because it has previ-
ously been reported that GSH concentrations are higher in
astrocytes than in neurons (Dringen, 2000), this suggests that
differences inGSHmetabolismmay explain, togetherwith higher
Glo-1 and -2 activities, the greater resistance of astrocytes against
MG toxicity. To assess this, we measured total intracellular GSH
levels ([GSx]i) as well as NADP and NADPH (the latter is essen-
tial for GSH recycling by GSH reductase; Fig. 1) in astrocytes and
neurons, following exposure to MG.
In control conditions, intracellular GSx concentrations were
on average ninefold higher in astrocytes compared with neurons
(118.7  7.6 and 13.7  0.5 nmol/mg protein in astrocytes and
neurons, respectively), and NADPH levels were threefold higher
in astrocytes comparedwith neurons (0.605 0.020 and 0.205
0.011 nmol/mg protein in astrocytes and neurons, respectively).
For dose–response analysis, cells were exposed to increasing con-
centrations of MG for 24 h. Subtoxic doses of MG (1 and 2 mM)
induced a large increase of intracellular GSH levels in astrocytes,
whereas higher doses produced a gradual decrease in GSH levels
(Fig. 5A), which correlated with MG toxicity in astrocytes (Fig.
4A). In contrast, no significant increase in intracellular GSH
could be observed following exposure to subtoxic doses ofMG in
neurons (Fig. 5B). Instead, GSH levels gradually decreased start-
ing at 500 M and became undetectable following exposure to 2
mM MG (Fig. 5B). NADPH concentration was significantly in-
creased in astrocytes following exposure to 2.5 mM MG but de-
creased gradually, together with NADP, in response to higher
concentrations of MG (Fig. 5C). Similar to the intracellular GSH
pattern, neurons did not display any compensatory increase in
NADPH; instead both NADP and NADPH levels were signif-
icantly decreased starting at 0.5 and 1 mM MG, respectively
(Fig. 5D).
For time course analyses,MGdoses in the lower toxicity range
were chosen (2.5 mM and 500 M for astrocytes and neurons,
respectively) to create a significant cellular stress. Exposure to
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Figure 4. MG toxicity in astrocytes and neurons. A, Dose-dependent decrease in astro-
cytic and neuronal viability following exposure to MG. Cells were treated with MG and
cellular viability was assessed 24 h later using the MTT assay. Results are expressed as a
percentage of control values and aremeans SEM of at least nine determinations from at
least three independent experiments. Data were statistically analyzed with one-way
ANOVA followed by Dunnett’s test (**p  0.01 vs controls). B, Pretreatment with the
carbonyl scavenger AG protects astrocytes and neurons against MG-induced toxicity as
assessed using the MTT assay. Different concentrations of MG were chosen to produce
robust toxicity in both cell types (3.5 and 1 mM MG for astrocytes and neurons, respec-
tively). Where indicated, an equimolar amount of AG (3.5 and 1 mM for astrocytes and
neurons, respectively) was added 30 min before the addition of MG and maintained
throughout the incubation period (24 h). Results are expressed as a percentage of control
(CTL) values and are means  SEM of at least nine determinations from at least three
independent experiments. Data were statistically analyzed with ANOVA followed by Bon-
ferroni’s test (***p  0.001 vs controls; ###p  0.001 vs MG). C, Astrocytes protect
neurons against MG toxicity in astrocyte–neuron cocultures. Primary neurons and cocul-
tures were exposed to the indicated doses of MG, and cellular viability was assessed in the
neuronal compartment using the MTT assay. Results are expressed as a percentage of
control values and are means SEM of at least eight determinations from at least three
independent experiments. Data were statistically analyzed with two-way ANOVA fol-
lowed by Bonferroni’s test (***p 0.001 vs primary neurons).
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MG lowered intracellular GSH levels in both cell types, with a
maximum decrease occurring 1 h following exposure to MG and
reaching 37 and 48% of control levels in astrocytes and neurons,
respectively (Fig. 6A,B). In astrocytes, GSH levels returned to
control values within 24 h (Fig. 6A), while in neurons GSH levels
did not recover within 24 h (Fig. 6B), despite the fact that they
were exposed to five times less MG than astrocytes. In astrocytes,
NADPH levels gradually increased over the first 3 h following
exposure toMG and remained significantly elevated for up to 6 h
(Fig. 6C). NADP levels remained unchanged following exposure
to MG, suggesting that compensatory mechanisms are activated
in astrocytes, leading to a net increase in NADPH synthesis. In
contrast, no significant change in NADP and NADPH levels
could be observed in neurons for up to 6 h following exposure to
MG (Fig. 6D).
The observed increases in the astrocytic GSH levels following
exposure to subtoxic doses of MG suggest that nuclear factor
(erythroid-derived 2)-like 2 (Nrf2)-dependent mechanisms
might be activated in this cell type. Indeed, this transcription
factor (which is primarily expressed in astrocytes in the CNS) can
be activated by decreases in the intracellular concentration of
GSH and plays a central role in inducible astrocytic defense
against oxidative stress, especially with regards to GSH synthesis
and release (Thimmulappa et al., 2002; Vargas and Johnson,
2009). Interestingly, we observed that exposure to MG induced
the expression of several antioxidant genes known to be under the
control of Nrf2, such as thioredoxin reductase, GSH synthetase,
GSH reductase, and the glutamate-cysteine ligase modifier subunit
(datanot shown).This suggests thatNrf2-dependentoxidative stress
defensemechanismsmightparticipate in the compensatory increase
in intracellularGSH levels observed in astrocytes in response to sub-
toxicdoses ofMG(Fig. 5A) andcontribute to their high resistance to
MG toxicity.
Differential MG-related protein modification in astrocytes
and neurons
We next conducted HPLC analyses to determine whether the
differences observed in the MG detoxification capacity of astro-
cytes and neurons have an impact on the cellular levels of MG
present in these two cell types. Results show that MG levels are
not significantly different between astrocytes and neurons (Fig.
7A). In addition, Western blot analysis using an antibody against
argpyrimidine (anMG-derivedAGE) shows that control cultures
of astrocytes and neurons display similar levels of argpyrimidine,
with the notable exception of two bands that were highly stained
for argpyrimidine in astrocytes (Fig. 7B, arrowheads). Interest-
ingly, several proteins bearing arginine hotspot sites for MG
modifications have previously been identified (Rabbani and
Thornalley, 2010). Further studies are warranted to determine
the identity of these argpyrimidine-modified proteins in astro-
cytes. This may provide useful information about the physiolog-
ical consequences of MG toxicity in this cell type.
When cultures were exposed to 500MMG, no increase in arg-
pyrimidine levels could be observed in astrocytes, while in contrast,
several proteins appeared tobemodifiedbyMGinneurons (Fig. 7B,
arrows), consistent with the fact that neurons detoxifyMG less effi-
ciently than astrocytes. Another indication of this was provided by
Western blot analysis using the 6D12 anti-AGE antibody, which has
been shown to recognize several AGE epitopes, including the
glyoxal-derived N-(carboxymethyl)lysine and the MG-derived
CEL (Koito et al., 2004; Nagai et al., 2008). Results revealed that
cultured neurons display very high levels of AGEs compared with
astrocytes in basal conditions (Fig. 7C).
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Figure 5. Dose–response effect of MG on the redox state of astrocytes and neurons. A, B,
Astrocytes (A) and neurons (B) were exposed to the indicated concentrations of MG, and total
intracellular GSH ([GSx]i) was measured 24 h later. Results are expressed as a percentage of
control (CTL) values and are means SEM of at least eight determinations from at least three
independent experiments. Data were statistically analyzed with ANOVA followed by Dunnett’s
test (*p 0.05; **p 0.01). C, D, Dose–response analysis of NADP and NADPH levels in
astrocytes (C) and neurons (D) following exposure to the indicated concentrations of MG for
24 h. Results aremeans SEMof at least nine determinations from at least three independent
experiments. Data were statistically analyzed with ANOVA followed by Dunnett’s test (**p
0.01 vs CTL NADPH levels; ##p 0.01 vs CTL NADP levels).
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Effects of modulations in the expression levels of Glo-1
RNA interference strategies against Glo-1were used to determine
whether theGlo-1 system is necessary for astrocytic and neuronal
survival. Transfection of astrocytes with siRNA targeted against
Glo-1 resulted in a 70%decrease of its activity asmeasured by the
glyoxalase enzymatic assay (30.4  3.1% of control values; Stu-
dent’s t test, p  0.001; n  7), while Glo-2 activity was not
significantly modified (95. 3  2.3% of control values; n  7).
Glo-1 downregulation was confirmed by Western blot analysis
(Fig. 8A). Glo-1 silencing did not itself induce any significant
decrease in cell viability in astrocytes (Fig. 8A); however, astro-
cytes in which Glo-1 expression was downregulated were signif-
icantly more vulnerable to MG toxicity (Fig. 8A).
Robust transfection of neuronal cultures with siRNA could
not be achieved in our hands. We thus opted for a lentivirus-
mediated shRNA knockdown strategy to achieve Glo-1 gene si-
lencing in neurons. Expression of Glo-1-specific shRNA in
neurons decreased Glo-1 activity (as assessed with the glyoxalase
enzymatic assay) in a similar range to that observed with siRNA
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in astrocytes (21.1 4.0% of control values; Student’s t test, p
0.001; n 6), while Glo-2 activity was not significantly decreased
(95. 5  6.7% of control values; n  6). Glo-1 downregulation
was confirmed by Western blot analysis (Fig. 8B). In contrast to
astrocytes, Glo-1 silencing alone induced a significant decrease in
neuronal viability (64.8 3.1% of negative control shRNA; p
0.001) (Fig. 8B). This was accompanied by a marked increase in
AGE levels (Fig. 8B), suggesting that an increase in dicarbonyl
compounds leading to the accumulation of toxic AGEs contrib-
utes to the loss of neuronal viability following Glo-1 downregu-
lation. Furthermore, neurons in which Glo-1 was silenced were
much more vulnerable to MG toxicity than neurons expressing
normal levels of Glo-1 (Fig. 8B).
To determinewhetherGlo-1-deficient neuronal cultures were
more sensitive to various substances known to induce neurode-
generation, Glo-1 shRNA-treated neuronal cultures were ex-
posed to 100 M diethylenetriamine-nitric oxide (DETA-NO)
for 24 h, 10 M glutamate for 4 h, or 25 M H2O2 for 4 h. Glo-1
silencing resulted in a significantly increased neuronal vulnera-
bility to NO, but did not significantly modify the susceptibility to
glutamate or H2O2 (Fig. 8C). Since NO has been shown to de-
crease Glo-1 expression and activity (Mitsumoto et al., 1999;
Miller et al., 2006), one can postulate thatNO-induced stressmay
impair the residual Glo-1 activity in Glo-1-deficient neurons,
leading to further neuronal death.
Considering the high susceptibility of neurons toGlo-1 silenc-
ing, we next sought to determine whether Glo-1 upregulation
could conversely protect neurons against various cellular stresses.
To this end, Glo-1 was overexpressed in neurons using lentiviral-
mediated gene delivery. The efficacy of Glo-1 overexpression us-
ing this approach was confirmed by Western blotting (Fig. 8D)
and by the glyoxalase enzymatic assay. Glo-1 overexpression re-
sulted in a 6.8-fold increase in Glo-1 activity (678.4  49.1% of
control values; n 10 from three independent experiments; p
0.001). This effect was specific to this enzyme, as Glo-2 activity
was not significantly changed (104.0  6.5% of control values;
n 10 from three independent experiments) in neurons overex-
pressing Glo-1. Despite this large increase in enzymatic activity,
Glo-1 overexpression did not significantly protect neurons
against MG (500 M for 24 h) or other neurotoxic substances,
including theNOdonorDETA-NO (100M for 24 h), glutamate
(10 M for 4 h), or H2O2 (25 M for 4 h) (Fig. 8D). These results
suggest that low expression levels of Glo-1 may not be the only
factor accounting for the high neuronal vulnerability to MG
toxicity.
Enhanced neuronal glycolysis leads to increase production
of MG
Recent reports have demonstrated that the poor capacity of
neurons to upregulate glycolysis (Almeida et al., 2001) is ex-
plained by the constitutive downregulation of Pfkfb3 (also
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are expressed as a percentage of controls and are means SEM of at least six determinations
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known as PFK-2, isoform 3). This enzyme is responsible for
the generation of fructose-2,6-P2, which is a key regulator of
glycolysis (Herrero-Mendez et al., 2009) (Fig. 1). Since MG
production is tightly linked to the glycolytic rate, the low pro-
tein expression levels of Pfkfb3 may represent a neuronal regula-
tory mechanism preventing MG toxicity, especially considering
that, as observed here, neurons have low MG detoxification
capacity. To test this hypothesis, we took advantage of the obser-
vationmadebyHerrero-Mendez et al. (2009) that overexpressionof
Pfkfb3 results in an increase of the glycolytic rate in cultured rat
neurons to manipulate glucose utilization in our neuronal cultures.
Long-termPfkfb3 overexpression was achieved using lentiviral-
mediated genedelivery and confirmedbyWesternblot analysis (Fig.
9A, top panel). As expected, increased Pfkfb3 expression in neurons
resulted in a significant stimulation of glucose utilization (119.8
3.1% of controls; p 0.001; Fig. 9A) together with a concomitant
increase in lactate release (265.3 38.6% of controls; p 0.001;
Fig. 9B). Remarkably, this stimulationof theneuronal glycolytic rate
was accompanied by a significant increase in intracellularMG levels
as determined by HPLC (Fig. 9C). In addition, Western blotting
analysis showed enhanced levels of argpyrimidine-modified pro-
teins inneuronsoverexpressingPfkfb3 (Fig. 9D), consistentwith the
observed increase inMG levels. As awhole, these results suggest that
a moderate increase in neuronal glycolytic rate can readily over-
whelm the glyoxalase system, leading to the accumulation of MG
and in turn resulting in protein damage in this cell type.
Discussion
For the first time, results of the present study demonstrate major
differences in the glyoxalase system of astrocytes and neurons,
which, together with marked disparities in GSH metabolism,
impact their respective capacity for cellular defense against glyca-
tion. Astrocytes displayed a much more efficient glyoxalase sys-
tem than neurons, as demonstrated by higher Glo-1/-2 protein
expression and enzymatic activity in vitro, as well as higher Glo-1
immunoreactivity and activity in the mouse brain. Astrocytic
Glo-1 activity rates observed here were also severalfold higher
compared with the high MG-producing CHO cells and with
those reported for various other cell types (Ranganathan et al.,
1995; Shinohara et al., 1998; Wu et al., 2001; Ahmed et al., 2003;
Kumagai et al., 2009), supporting the notion that astrocytes pos-
sess a particularly efficient glyoxalase system.
The detoxification of MG via the glyoxalase pathway requires
GSHas a cofactor. It has previously been reported thatGSH levels
are significantly higher in astrocytes than in neurons (Dringen,
2000). Consistent with these reports, our results show that intra-
cellular GSH and NADPH levels were, respectively, ninefold and
threefold higher in astrocytes. Furthermore, astrocytes displayed
greater metabolic plasticity with regards to GSH and NADPH, as
demonstrated by a compensatory increase of both metabolites in
response to subtoxic doses of MG, by the activation of Nrf2-
dependent antioxidant defense mechanisms, and by the capacity
of astrocytes to recover normal GSH levels following a transient
MG-induced decrease. These differences in GSH metabolism,
together with a higher glyoxalase activity, confer to astrocytes
greater resistance to exogenousMG. Consistently, previous stud-
ies have reported a high neuronal susceptibility to MG toxicity,
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***p0.001).D,Western blot analysis shows increasedneuronal argpyrimidine levels follow-
ing Pfkfb3 overexpression. Representative bands are shown. Similar results were obtained in
three independent experiments (n 8).
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which was associated with oxidative stress leading to apoptosis
(Kikuchi et al., 1999; Di Loreto et al., 2008; Chen et al., 2010).
Considering that CSF levels are between 10 and 20M (Kuhla
et al., 2005), and cellular levels of free MG are typically in the low
micromolar range (Rabbani and Thornalley, 2010), the LD50 val-
ues observed here for MG in astrocytes and neurons may appear
quite high. However, MG is highly reactive and is expected to
have a short half-life in the cellular environment; therefore, local
concentration at the time and site of production may be signifi-
cantly higher (Kalapos, 2008b). Interestingly, it is estimated that
90–99% of cellular MG is bound to macromolecules, and assess-
ments of total (bound free) MG showed that cellular concen-
trations up to 300 M can be measured (Thornalley, 1996;
Chaplen et al., 1998).
Despite the fact that cultured astrocytes display 3 times
higher glycolytic rate than neurons in basal conditions (Magis-
tretti and Pellerin, 1996), we did not see any differences in endog-
enous MG levels between these two cell types, which may be
explained by the more efficient glyoxalase system present in as-
trocytes. Consistent with this, Western blot analysis showed
higher levels of MG and glyoxal-derived AGEs in neurons com-
pared with astrocytes using the 6D12 anti-AGE antibody.
Previous reports have demonstrated that Glo-1 overexpres-
sion protects against increased AGE formation and/or oxidative
stress associated with aging, hyperglycemia, and ischemia-
reperfusion injury (Shinohara et al., 1998; Morcos et al., 2008;
Kumagai et al., 2009; Schlotterer et al., 2009; Brouwers et al.,
2011). However, in our hands Glo-1 overexpression did not pro-
tect cortical neurons against MG toxicity. One possible explana-
tion for this is that, as discussed above, cultured cortical neurons
have particularly low levels of GSH and a poor capacity to replen-
ish the GSH pool following exposure to MG. GSH levels may
therefore be a limiting factor forMGdetoxification in neurons, in
which caseGlo-1 overexpressionwould not be sufficient to afford
neuroprotection. Further studies are warranted to clarify this is-
sue. In contrast with the lack of effect of Glo-1 overexpression, its
downregulation induced a significant loss of viability in neurons
but not in astrocytes, indicating that (1) Glo-1 is essential for
neuronal viability and that (2) in contrast with neurons, astro-
cytes express Glo-1 in excess of the levels required for their sur-
vival in the absence of a major cellular stress.
Astrocytes are key players in themaintenance of brain homeo-
stasis, and several cooperative metabolic processes and interde-
pendencies between astrocytes and neurons have been identified
(Be´langer andMagistretti, 2009; Allaman et al., 2011). For exam-
ple, it is well established that astrocytes protect neurons against
oxidative stress and excitotoxicity (Rothstein et al., 1996; John-
son et al., 2008; Vargas and Johnson, 2009). Here, we show that
astrocytes protect neurons against MG toxicity in a coculture
model. This conceivably represents another level of astrocyte–
neuron cooperativitywhereby a highly efficient glyoxalase system
in astrocytes may contribute to neuronal protection against MG
potentially leaking from the periphery, the CSF, or surrounding
cells.
The differential Glo-1 efficiency observed in astrocytes and
neurons may relate to their dissimilar metabolic profile. Numer-
ous reports have shown that astrocytes display high metabolic
plasticity in terms of glucose utilization, which is not the case for
neurons (Pellerin and Magistretti, 1994; Almeida et al., 2001;
Prapong et al., 2002; Porras et al., 2004; Gavillet et al., 2008;
Allaman et al., 2010; Be´langer et al., 2011). One striking example
is the differential response of astrocytes and neurons following
the inhibition of mitochondrial respiration by NO. Unlike neu-
rons in which NO leads to a massive ATP depletion and apopto-
sis, astrocytes respond by increasing glycolysis, which limits the
fall in ATP levels and prevents apoptosis (Almeida et al., 2001).
This astrocytic response is dependent upon the synthesis of fruc-
tose-2,6-P2—a potent activator of the glycolytic enzyme phos-
phofructokinase-1—by the enzyme Pfkfb (Almeida et al., 2004).
While this enzyme is highly expressed in astrocytes, it is virtually
absent in neurons due to its constant proteasomal degradation
(Herrero-Mendez et al., 2009). Furthermore, the activation of
neuronal glycolysis via Pfkfb3 overexpression leads to oxidative
stress and apoptosis (Herrero-Mendez et al., 2009). Interestingly,
similar to Pfkfb3, the enzymaticmachinery for glycogen synthesis
is tightly suppressed in neurons—hence the virtual absence of
glycogen in this cell type—and failure to do so also results in
neuronal apoptosis (Vilchez et al., 2007). Thus, two pathways
directly linked to triosephosphate metabolisms are tightly re-
pressed in neurons and lead to apoptosis if activated.
Our results suggest that high neuronal susceptibility to MG
toxicity may in part be involved in the deleterious effects of in-
creasing the glycolytic fluxes in these cells. While Pfkfb3 overex-
pression did not induce significant neuronal death in our
hands—possibly because the increases in glucose utilization
achieved here using a different species and another gene trans-
duction system were modest compared with those previously
reported (Herrero-Mendez et al., 2009)—even a moderate in-
crease in neuronal glycolysis was sufficient to significantly in-
crease MG and AGE levels. This observation suggests that a
limited capacity to face deleterious dicarbonyl stress may in part
explain why neurons constitutively suppress pathways poten-
tially leading to MG formation.
These observations may also provide insight into the reason
why astrocytes can sustain a higher basal glycolytic rate than neu-
rons, and why neurons depend on astrocytes tomeet their energy
needs—as proposed by the ANLS model and substantiated by
several in vitro, ex vivo, and in vivo data (Kasischke et al., 2004;
Porras et al., 2004; Rouach et al., 2008; Magistretti, 2009; Chu-
quet et al., 2010). Considering that glucosemetabolism inevitably
leads to MG formation, lactate utilization may provide a means
for neurons to alleviate MG toxicity by decreasing their glucose
utilization, yet meet their high energetic requirements by using
astrocyte-derived lactate, which can be oxidized in the Krebs cy-
cle following its conversion to pyruvate. Most of the MG burden
associated with a high glycolytic flux would thus be left to the
astrocytes, which according to our data are better equipped to
handle it.
Interestingly, modulations of the glyoxalase system have been
observed in aging and various neuropathological conditions. For
instance, Glo-1 expressionwas reported to decrease progressively
in the human brain starting from the fifth decade (Kuhla et al.,
2006), in correlation with increased AGE levels in neurons and
astrocytes (Lu¨th et al., 2005). Impaired Glo-1 activity may thus
contribute to the pathogenesis of neurodegenerative disorders,
considering that MG induces oxidative stress and AGE forma-
tion, which are major factors involved in many of these age-
dependent pathologies. For example, in Alzheimer’s disease
(AD), Glo-1 expression is increased in early stages, but then de-
creases below normal levels at later stages, correlating with a
marked increase inAGE accumulation (Lu¨th et al., 2005; Kuhla et
al., 2007). AGEs colocalize with amyloid- plaques and neurons
containing hyperphosphorylated tau protein in AD brains, but
astrocytes are also affected as they show increased AGE and in-
ducible nitric oxide synthase immunoreactivity (Wong et al.,
2001; Lu¨th et al., 2005). While further studies are warranted to
18350 • J. Neurosci., December 14, 2011 • 31(50):18338–18352 Be´langer et al. • The Glyoxalase System in Astrocytes and Neurons
clarify the specific effects on different neural cell types, strong
evidence suggests that the glyoxalase system is impaired in AD,
which may participate in the vicious circle of amyloid- deposi-
tion, AGE formation, and oxidative stress associated with this
disease.
In conclusion, results of the present study show that the glyox-
alase pathway differs significantly between astrocytes and neu-
rons in a way that renders neurons more vulnerable to carbonyl
stress and AGE accumulation. These results support the notion
that the metabolic specialization taking place in brain cells—
astrocytes are more glycolytic than neurons—may help protect
neurons from MG toxicity.
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